Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has issued an announcement.
Fusen Pharmaceutical said its wholly owned unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology has secured National Medical Products Administration approval in China to market Dydrogesterone Tablet, branded Yunmeiyan, for a range of conditions linked to endogenous progesterone deficiency. The orally administered synthetic progestogen is positioned as a safer, more bioavailable alternative to natural and traditional synthetic progesterones, is classified as a Class B drug under China’s national insurance system, and taps a sizeable domestic market that generated about RMB2.5 billion in 2025, marking a significant expansion of Fusen’s gynecology and reproductive health portfolio and broadening treatment options for patients.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited is a Cayman Islands-incorporated drug maker listed in Hong Kong, operating through subsidiaries such as Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology in mainland China. The group focuses on developing and marketing prescription medicines, with a growing pipeline that includes therapies targeting gynecological and reproductive health indications in the Chinese market.
Average Trading Volume: 632,859
Technical Sentiment Signal: Buy
Current Market Cap: HK$882.3M
For an in-depth examination of 1652 stock, go to TipRanks’ Overview page.